ClinicalTrials.gg
CompletedNCT06190340Updated Feb 27, 2025Results posted

A Phase 1 Study to Evaluate PK Profile of Multiple Oral Administrations of TNP-2092 Capsules in Healthy Subjects

A Phase 1 interventional study of TNP-2092 capsules and Placebo in Helicobacter Pylori Infection, sponsored by TenNor Therapeutics (Suzhou) Limited. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by TenNor Therapeutics (Suzhou) Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 years 1 month after the study started (first participant enrolled Nov 2016, registered Dec 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study was a single-center, randomized, double-blind, placebo-controlled, dose-ascending multiple-dose-administration study. The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic profile of TNP-2092 Capsules in asymptomatic healthy subjects with Helicobacter pylori infection, and to explore the preliminary efficacy of TNP-2092 Capsules in eradicating Helicobacter pylori.

Read the detailed description

This study was a single-center, randomized, double-blind, placebo-controlled, dose-ascending multiple-dose-administration study. The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic profile of TNP-2092 Capsules in asymptomatic healthy subjects with Helicobacter pylori infection, and to explore the preliminary efficacy of TNP-2092 Capsules in eradicating Helicobacter pylori.

In this study, three dose groups of 100 mg, 300 mg and 600 mg will be set up. The drug will be taken twice a day for 14 consecutive days, and last dose on the morning of Day 15. Fifteen subjects in each of the 100 mg and 300 mg dose groups will be randomized at a ratio of 4:1, with 12 subjects receiving the investigational product and 3 receiving placebo. Ten subjects in the 600 mg dose group will be randomized at a ratio of 4:1, with 8 subjects receiving the investigational product and 2 subjects receiving placebo.

02

Conditions studied

  • Helicobacter Pylori Infection
03

In context

Lead sponsor

TenNor Therapeutics (Suzhou) Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Those who are fully informed of and understand this study and have signed the Form.
  • Those who are willing to follow and able to complete all the trial procedures.
  • Female subjects of must agree to abstinence or take effective measures during the trial and at least 70 days (10 weeks) after administration.
  • Male subjects must agree to abstinence or use condoms as a contraceptive measure during the trial and at least 70 days (10 weeks) after administration.
  • Sex: male or female.
  • Age: 18-45 years, including 18 and 45 years.
  • : 19.0-26.0 kg/m2, including 19.0 and 26.0 kg/m2.
  • Those who do not smoke, or have smoked less than 5 cigarettes per day within 3 months before screening; those who do not drink alcohol, or have drunk less than 14 units of alcohol per week (1 unit of alcohol = 360 mL of beer or 45 mL of spirits with 40% alcohol content or 150 mL of wine) within 6 months before screening; those who have not smoked or drunk alcohol within 48 hours before admission to the study site.
  • Subjects whose clinical laboratory test results are within the normal range or whose test results are abnormal but judged by the investigator to be of no clinical insignificance.
  • Those with a positive 14C urea breath test (UBT) result.

Exclusion criteria

Exclusion Criteria:

  • Those with an allergic constitution, a history of allergic diseases or a history of drug allergy.
  • Those with a history of alcohol or drug abuse in the past 10 years.
  • Those who have donated blood within 3 months before enrollment.
  • Those with regular use of any prescription/over-the-counter drugs, including vitamins, minerals, nutritional supplements or herbs, within 2 weeks before enrollment and during the study period.
  • Those who have taken any drug that changes the activity of liver enzymes 28 days before taking the product or during the study.
  • Those who have participated in any clinical trials within 3 months before enrollment.
  • Those with a history of eradication of Helicobacter pylori.
  • Those who are suffering or have suffered from digestive tract diseases, including digestive tract ulcer, etc.
  • Those with symptoms or past medical history of cardiovascular, respiratory, urinary, neurological, blood, immune, endocrine system diseases or tumor, mental illness, or any situation which, in the opinion of the investigator, may threaten the safety of the subjects or affect the correctness of the trial results.
  • Those whose blood pressure remains above 140/90 mmHg after retest.
  • Pregnant or lactating women.
  • Those who are positive, syphilis positive, surface antigen positive, antibody positive.
  • Those who have had beverages or foods containing methylxanthine (coffee, tea, coke, chocolate, and energy drinks), grapefruit (fruit juice) and alcohol within 48 hours (2 days) before the clinical study.
  • Other circumstances deemed by the investigator to be unsuitable for the subject to participate in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    TNP-2092 capsules 100 mg

    Subjects received TNP-2092 capsules orally twice daily at the dose of 100 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15

    Drug: TNP-2092 capsules

  • Experimental
    TNP-2092 capsules 300 mg

    Subjects received TNP-2092 capsules orally twice daily at the dose of 300 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15

    Drug: TNP-2092 capsules

  • Experimental
    TNP-2092 capsules 600 mg

    Subjects received TNP-2092 capsules orally twice daily at the dose of 600 mg in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15

    Drug: TNP-2092 capsules

  • Placebo comparator
    Placebo

    Subjects received TNP-2092 placebo capsules orally twice daily in the fed state for consecutive 14 days and received the last dose in the fed state on the morning of Day 15

    Drug: Placebo

Interventions

  • Administration orally.

    Also known as: Rifaquizinone capsules

  • DrugPlacebo

    Administration orally.

    Also known as: TNP-2092 placebo capsules

06

What researchers measure

Primary outcomes

  1. Safety of TNP-2092 by Assessment of the Number of Adverse Events (AEs)

    An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

    Time frame: Day 1 to Day 49

  2. Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 1

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration

  3. Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 1

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration

  4. Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration

  5. Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) on Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration

  6. Area Under the Plasma Concentration Versus Time Curve From the First Administration to the Last Measurable Plasma Concentration (AUC0-last) on Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration

  7. Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration

  8. Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration

  9. Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration

  10. Half Life (t1/2) of TNP-2092 on Day 15

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

    Time frame: Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration

  11. Number of Participants With Negative Results of 14 Urea Breath Test (14C UBT) at 4 to 6 Weeks After Last Dose

    Participants received 14 urea breath test \[14C UBT\] at 4 to 6 weeks after last dose.

    Time frame: Four to 6 weeks after the last dose of the study drugs.

  12. Accumulation Index Rac (AUC) of TNP-2092

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (AUC) is calculated from the ratio of AUC0-tau (Day 15) to AUC0-tau(Day 1).

    Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration. Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration

  13. Accumulation Index Rac(Cmax) of TNP-2092

    Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (Cmax) is calculated from the ratio of Cmax (Day 15) to Cmax (Day 1).

    Time frame: Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration. Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration

07

Results

Posted Jan 29, 2025

Participant flow

Participant flow — Overall Study
MilestoneTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mgPlacebo
Started121288
Completed121288
Not completed0000

Outcome measures

PrimarySafety of TNP-2092 by Assessment of the Number of Adverse Events (AEs)

An Adverse Event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.

Time frame:
Day 1 to Day 49
Reported as:
Number · participants
Safety of TNP-2092 by Assessment of the Number of Adverse Events (AEs)
participantsTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mgPlacebo
Safety of TNP-2092 by Assessment of the Number of Adverse Events (AEs)6943
PrimaryArea Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 1

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration
Reported as:
Mean · h*µg/L
Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 1
h*µg/LTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 162.8 ± 34.4190 ± 86.5618 ± 310
PrimaryMaximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 1

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration
Reported as:
Mean · µg/L
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 1
µg/LTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 117.7 ± 8.3846.4 ± 21.7149 ± 78.4
PrimaryTime to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration
Reported as:
Mean · h
Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 1
hTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Time to Reach the Maximum Observed Plasma Concentration (Tmax) on Day 14 ± 14 ± 14 ± 0.8
PrimaryArea Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) on Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Reported as:
Mean · h*µg/L
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) on Day 15
h*µg/LTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf) on Day 1596.5 ± 46.5274 ± 114701 ± 274
PrimaryArea Under the Plasma Concentration Versus Time Curve From the First Administration to the Last Measurable Plasma Concentration (AUC0-last) on Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Reported as:
Mean · h*µg/L
Area Under the Plasma Concentration Versus Time Curve From the First Administration to the Last Measurable Plasma Concentration (AUC0-last) on Day 15
h*µg/LTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Area Under the Plasma Concentration Versus Time Curve From the First Administration to the Last Measurable Plasma Concentration (AUC0-last) on Day 1593.3 ± 46.1267 ± 112692 ± 272
PrimaryArea Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma PK parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Reported as:
Mean · h*µg/L
Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 15
h*µg/LTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Area Under the Plasma Concentration Versus Time Curve Over a Dosing Interval (AUC0-tau) on Day 1590.7 ± 41.1250 ± 105657 ± 257
PrimaryMaximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Reported as:
Mean · µg/L
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 15
µg/LTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Maximum Observed Plasma Concentration (Cmax) of TNP-2092 on Day 1521.7 ± 9.3559.9 ± 30.2167 ± 75.6
PrimaryTime to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Reported as:
Mean · h
Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 15
hTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Time to Reach the Maximum Observed Plasma Concentration (Tmax) Day 154 ± 0.93 ± 24 ± 0.5
PrimaryHalf Life (t1/2) of TNP-2092 on Day 15

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.

Time frame:
Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Reported as:
Mean · h
Half Life (t1/2) of TNP-2092 on Day 15
hTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Half Life (t1/2) of TNP-2092 on Day 153.26 ± 1.297.3 ± 4.916.67 ± 2.57
PrimaryNumber of Participants With Negative Results of 14 Urea Breath Test (14C UBT) at 4 to 6 Weeks After Last Dose

Participants received 14 urea breath test \[14C UBT\] at 4 to 6 weeks after last dose.

Time frame:
Four to 6 weeks after the last dose of the study drugs.
Reported as:
Number · participants
Number of Participants With Negative Results of 14 Urea Breath Test (14C UBT) at 4 to 6 Weeks After Last Dose
participantsTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mgPlacebo
Number of Participants With Negative Results of 14 Urea Breath Test (14C UBT) at 4 to 6 Weeks After Last Dose1101
PrimaryAccumulation Index Rac (AUC) of TNP-2092

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (AUC) is calculated from the ratio of AUC0-tau (Day 15) to AUC0-tau(Day 1).

Time frame:
Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration. Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Reported as:
Mean · ratio
Accumulation Index Rac (AUC) of TNP-2092
ratioTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Accumulation Index Rac (AUC) of TNP-20921.65 ± 0.541.51 ± 0.991.19 ± 0.61
PrimaryAccumulation Index Rac(Cmax) of TNP-2092

Plasma concentrations of TNP-2092 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2092 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods. Rac (Cmax) is calculated from the ratio of Cmax (Day 15) to Cmax (Day 1).

Time frame:
Day 1:Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after administration. Day 15: Before administration (within 60 minutes), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48 and 72 hours after administration
Reported as:
Mean · ratio
Accumulation Index Rac(Cmax) of TNP-2092
ratioTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mg
Accumulation Index Rac(Cmax) of TNP-20921.36 ± 0.461.61 ± 1.561.24 ± 0.66

Adverse events

Collected over Day 1 to Day 49. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TNP-2092 Capsules 100 mg0/12 (0%)0/12 (0%)6/12 (50%)
TNP-2092 Capsules 300 mg0/12 (0%)0/12 (0%)9/12 (75%)
TNP-2092 Capsules 600 mg0/8 (0%)0/8 (0%)4/8 (50%)
Placebo0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventTNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mgPlacebo
Alanine aminotransferase increasedInvestigations3/123/123/80/8
Aspartate aminotransferase increasedInvestigations3/122/122/80/8
Urinary tract infectionInfections and infestations1/122/121/80/8
RashSkin and subcutaneous tissue disorders0/122/120/80/8
Upper respiratory tract infectionInfections and infestations0/121/120/81/8
White blood cell count increasedInvestigations1/120/120/81/8
White blood cells urine positiveInvestigations0/120/121/80/8
Blood albumin decreasedInvestigations0/120/120/81/8
HeadacheNervous system disorders0/120/120/81/8
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/120/120/81/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)TNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mgPlaceboTotal
<=18 years00000
Between 18 and 65 years12128840
>=65 years00000
Age, Continuous
Age, Continuous(years)TNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mgPlaceboTotal
Mean29.4 ± 7.9932.7 ± 7.7533.5 ± 5.7834.0 ± 6.7032.1 ± 7.24
Sex: Female, Male
Sex: Female, Male(Participants)TNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mgPlaceboTotal
Female344213
Male984627
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mgPlaceboTotal
American Indian or Alaska Native00000
Asian12128840
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Positive rates of carbon 14 urea breath test (14C UBT)
Positive rates of carbon 14 urea breath test (14C UBT)(Participants)TNP-2092 Capsules 100 mgTNP-2092 Capsules 300 mgTNP-2092 Capsules 600 mgPlaceboTotal
Count of participants12128840
08

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Sep 2017, 10 months.

Results were first posted in Jan 2025, 7 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2023
First posted
Jan 5, 2024
StartActual
Nov 8, 2016
Primary completionActual
Sep 26, 2017
CompletionActual
Sep 26, 2017
Results first posted
Jan 29, 2025
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06190340
Lead sponsor
TenNor Therapeutics (Suzhou) Limited
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Nov 8, 2016
Primary completion
Sep 26, 2017
Completion
Sep 26, 2017
Results posted
Jan 29, 2025
Last update
Feb 27, 2025

Study contacts

Yanhua Ding, MD
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TNP-2092

Start the discussion